Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSitePREPRINT
November 28, 2021
by Leo Goldstein
Contact [email protected]
Can be cited as: Goldstein L., Re-analysis of Molnupiravir Trials, Phase II/III; defyccc.com, PREPRINT, [link], 2021
This is a re-analysis of the data from Molnupiravir trials, presented by the FDA.
The trials’ sponsor modified the pre-registered protocol, so the results will appear more beneficial than they are. To this end, results from patients recruited by August 5 were reported as a separate trial – here referred to as Trial 1. Thus, the data from patients recruited after August 5 should also be presented as a separate trial – here referred to as Trial 2.
In this second trial, the Molnupiravir arm had 32.5% higher relative risk of hospitalization or death compared to the placebo arm.
Both trials show that starting Molnupiravir treatment later (more then 3 days after symptom onset) is associated with better outcomes than starting the treatment earlier (less then 3 days from symptom onset). This is consistent with the hypothesis that Molnupiravir harms th...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).